Affiliate disclosure: some links on this page are affiliate links and may earn us a commission at no extra cost to you — it never affects our rankings or reviews.

Guide · Medicare · United States

Does Medicare cover Ozempic?

Not for weight loss: Ozempic is not a Bridge drug, and Medicare Part D cannot cover medicines used for weight loss. Part D plans may cover Ozempic for type 2 diabetes, depending on the plan's formulary; for weight management, the Bridge covers Wegovy, which has the same active ingredient (semaglutide), for $50 a month if you are eligible.

Every fact on this page carries its source and date; we read them on October 30, 2026. This is general information, not advice about your plan or your health: a clinician decides whether a medicine is right for you, and Medicare or your plan decides coverage.

Edited by Gabriel BrocklesbyFounder & EditorFact-checkedLast updated

Ozempic for type 2 diabetes: your Part D plan

Part D plans may cover Ozempic for type 2 diabetes, subject to each plan's formulary and, possibly, prior authorization. No single source says every plan covers it, so check your own plan's formulary or call the plan.

Medicare.gov's fact sheet says people with type 2 diabetes should contact their Medicare drug plan, which may already cover a GLP-1.

Sources: Medicare.gov fact sheet: Medicare GLP-1 Bridge (CMS Product No. 12234) (June 2026); CMS: Medicare GLP-1 Bridge expectations and FAQs for Part D sponsors (June 10, 2026). Read October 30, 2026.

Ozempic for weight loss: not covered

Ozempic is not a Bridge drug: the Medicare GLP-1 Bridge (July 1, 2026 to December 31, 2027) covers Foundayo (tablet), Wegovy (injection or tablet), Zepbound KwikPen, and Ozempic is not on the list. Part D law excludes drugs "when used for anorexia, weight loss, or weight gain", so a Part D plan cannot cover Ozempic for weight loss either.

For weight management, the Bridge covers Wegovy, which contains semaglutide, the same active ingredient as Ozempic, for $50 a month for eligible people with Part D coverage and prior authorization. Wegovy and Ozempic are different products, and a clinician decides which, if either, is right for you.

Sources: Medicare.gov fact sheet: Medicare GLP-1 Bridge (CMS Product No. 12234) (June 2026); Congressional Research Service In Focus IF12758 (September 9, 2024); CMS: Medicare GLP-1 Bridge (page last modified July 13, 2026). Read October 30, 2026.

If you are thinking of the Bridge instead

The Bridge is for weight management only. People with type 2 diabetes are excluded from it and use their Part D plan, as are people already getting a GLP-1 such as semaglutide through Part D.

  • Eligibility: 18 or older, with a BMI of 35 or higher; or a BMI of 30 or higher with heart failure with preserved ejection fraction (HFpEF), uncontrolled high blood pressure (systolic above 140 or diastolic above 90 despite two blood pressure medicines) or chronic kidney disease stage 3a or later; or a BMI of 27 or higher with prediabetes, a previous heart attack, a previous stroke or symptomatic peripheral artery disease.
  • Cost: $50 a month; the Part D deductible does not apply and Extra Help does not reduce it.
  • Prior authorization: your prescriber submits it; a decision comes within 72 hours.

Sources: CMS prescriber fact sheet (No. 12235) (June 2026); Medicare.gov fact sheet: Medicare GLP-1 Bridge (CMS Product No. 12234) (June 2026); CMS: Medicare GLP-1 Bridge expectations and FAQs for Part D sponsors (June 10, 2026). Read October 30, 2026.

From 2027: the Medicare negotiated price for semaglutide

From January 1, 2027, the Medicare negotiated price (maximum fair price) for semaglutide is $274 for the group: $276.78 for an Ozempic 4 mg/3 mL pen and $385.63 for Wegovy 4 x 2.4 mg, a 71% cut from the 2024 list price of $959. It applies to Part D-covered uses only, not weight loss. This is the price Medicare pays, not your copay. We read AMCP's summary of the CMS release; the CMS release itself could not be fetched.

Source: AMCP federal update: CMS releases IPAY 2027 negotiated prices (November 2025). Read October 30, 2026.

If you are not eligible, or not covered

The Bridge ends on December 31, 2027. CMS has not said what follows: its page says only that Bridge data may inform a possible BALANCE model in Part D, and KFF (April 23, 2026) says CMS's approach after the Bridge is unknown.

The manufacturer sells Ozempic direct for cash, with a prescription you already hold. We list these prices for information; PCF has no commercial relationship with the manufacturer.

  • NovoCare Pharmacy lists the Ozempic pill at $149 a month at the starting dose, checked November 19, 2026. No membership printed, prescription required. NovoCare Pharmacy's page
  • NovoCare Pharmacy lists the Ozempic pen at $199 a month at the starting dose ("Offer for 2 monthly fills through December 31, 2026"; then $349 per month), checked November 19, 2026. No membership printed, prescription required. NovoCare Pharmacy's page

Medicare enrollees can use NovoCare self-pay but must agree not to count the cost toward their Part D deductible or out-of-pocket limit (NovoCare's Ozempic terms). Prices are read daily from each seller's own page; see the brand-name GLP-1 price chart for every seller.

Sources: CMS: Medicare GLP-1 Bridge (page last modified July 13, 2026); KFF: CMS extends Medicare's short-term Bridge program for GLP-1 obesity drug coverage (April 23, 2026); NovoCare: Ozempic self-pay pricing and terms (no page date). Read October 30, 2026.

Frequently asked questions

Does Medicare cover Ozempic for weight loss?

No. Ozempic is not a Bridge drug (Medicare.gov fact sheet, June 2026), and Part D law excludes drugs used for weight loss (CRS, September 9, 2024). For weight management, the Bridge covers Wegovy for $50 a month if you are eligible.

Does Medicare cover Ozempic for type 2 diabetes?

Part D plans may cover it for type 2 diabetes, depending on the plan's formulary and, possibly, prior authorization. Check your plan's formulary.

Is Ozempic part of the Medicare GLP-1 Bridge?

No. The Bridge covers Foundayo (tablet), Wegovy (injection or tablet), Zepbound KwikPen (Medicare.gov fact sheet, June 2026). Mounjaro is not on the list either.

Why does Medicare cover Wegovy but not Ozempic for weight loss?

The Bridge is a CMS demonstration that lists specific products, and Ozempic is not one of them. Wegovy is on the list. Both contain semaglutide, but they are different products, and a clinician decides which, if either, is appropriate.

Will Ozempic be cheaper under Medicare from 2027?

From January 1, 2027, the Medicare negotiated price for an Ozempic 4 mg/3 mL pen is $276.78, for Part D-covered uses only (AMCP summary of the CMS release, November 2025). That is what Medicare pays; your copay depends on your plan.